Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound 55 is a brain-penetrant indoline-2-carboxamide derivative developed by the University of Dundee's Drug Discovery Unit for the treatment of Human African Trypanosomiasis (HAT), also known as sleeping sickness. Identified through phenotypic screening of a focused protease inhibitor library against *Trypanosoma brucei*, the compound is chemically characterized as a 5-fluoroindoline with a 4-fluorophenyl pendant ether moiety. It demonstrated potent antiproliferative activity against the parasite and showed high metabolic stability with favorable brain tissue distribution. While the compound achieved full cures in stage 1 (hemolymphatic) mouse models of HAT, its development was ultimately terminated due to dose-limiting tolerability issues that prevented the delivery of a fully curative regimen in stage 2 (meningoencephalitic) models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound 55 (University of Dundee).